C11orf87

Summary

C11orf87 (chromosome 11 open reading frame 87, HGNC:33788) is a protein-coding gene on chromosome 11q22.3, encoding Uncharacterized protein C11orf87 (Q6NUJ2).

Predicted to be located in membrane.

Source: NCBI Gene 399947 — RefSeq curated summary.

At a glance

• GWAS associations: 10
• Clinical variants (ClinVar): 3 total
• MANE Select transcript: NM_207645

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:33788
Approved symbol	C11orf87
Name	chromosome 11 open reading frame 87
Location	11q22.3
Locus type	gene with protein product
Status	Approved
Aliases	LOH11CR1A, LOC399947, NEURIM1
Ensembl gene	ENSG00000185742
Ensembl biotype	protein_coding
Entrez	399947

Gene structure

Transcript identifiers

Ensembl transcripts: 5 — 5 protein_coding

ENST00000327419, ENST00000907963, ENST00000907964, ENST00000907965, ENST00000907966

RefSeq mRNA: 1 — MANE Select: NM_207645 NM_207645

CCDS: CCDS31672

Canonical transcript exons

ENST00000327419 — 2 exons

Exon	Start	End
ENSE00001305459	109422190	109422263
ENSE00001330903	109423375	109429167

Expression profiles

Bgee: expression breadth broad, 93 present calls, max score 96.05.

FANTOM5 (CAGE): breadth broad, TPM avg 3.3741 / max 150.3060, expressed in 351 samples.

FANTOM5 promoters (8 alternative TSS)

Promoter ID	TPM avg	Samples expressed
116554	2.6423	321
116553	0.3017	103
116555	0.1799	85
116552	0.1593	67
116551	0.0393	26
116559	0.0198	8
116557	0.0175	4
116558	0.0143	6

Top tissues by expression

234 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
endothelial cell	CL:0000115	96.05	gold quality
lateral nuclear group of thalamus	UBERON:0002736	95.66	gold quality
Brodmann (1909) area 23	UBERON:0013554	93.02	gold quality
Brodmann (1909) area 46	UBERON:0006483	90.45	gold quality
primary visual cortex	UBERON:0002436	89.84	gold quality
middle temporal gyrus	UBERON:0002771	89.54	gold quality
occipital lobe	UBERON:0002021	89.24	gold quality
prefrontal cortex	UBERON:0000451	89.19	gold quality
frontal cortex	UBERON:0001870	87.16	gold quality
superior frontal gyrus	UBERON:0002661	86.69	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	86.58	gold quality
Brodmann (1909) area 9	UBERON:0013540	86.12	gold quality
neocortex	UBERON:0001950	85.65	gold quality
parietal lobe	UBERON:0001872	84.25	gold quality
cerebral cortex	UBERON:0000956	84.16	gold quality
right frontal lobe	UBERON:0002810	83.28	gold quality
postcentral gyrus	UBERON:0002581	82.99	gold quality
pons	UBERON:0000988	81.29	gold quality
anterior cingulate cortex	UBERON:0009835	81.20	gold quality
entorhinal cortex	UBERON:0002728	80.74	gold quality
cortical plate	UBERON:0005343	77.61	gold quality
Ammon’s horn	UBERON:0001954	77.04	gold quality
nucleus accumbens	UBERON:0001882	76.83	gold quality
temporal lobe	UBERON:0001871	76.05	gold quality
forebrain	UBERON:0001890	76.00	gold quality
buccal mucosa cell	CL:0002336	75.95	gold quality
ganglionic eminence	UBERON:0004023	75.53	gold quality
brain	UBERON:0000955	74.12	gold quality
caudate nucleus	UBERON:0001873	73.44	gold quality
putamen	UBERON:0001874	73.35	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	3.60

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

284 targeting C11orf87, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-4476	100.00	68.18	2030
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-4668-3P	100.00	68.74	2635
HSA-MIR-3162-3P	100.00	65.37	363
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-29A-3P	100.00	73.11	1835
HSA-MIR-29B-3P	100.00	73.18	1833
HSA-MIR-29C-3P	100.00	73.15	1833
HSA-MIR-4510	100.00	66.60	2050
HSA-MIR-6127	100.00	66.76	2188
HSA-MIR-6129	100.00	66.46	2080
HSA-MIR-6130	100.00	66.69	2012
HSA-MIR-6133	100.00	66.48	2064
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-5193	100.00	67.26	1744
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-4747-5P	100.00	67.90	2681
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-190A-3P	100.00	80.35	5520

Literature-anchored findings (GeneRIF, showing 2)

• Suppression of miR-147b contributed to H37Rv-infected macrophage viability and migration in tuberculosis in vitro. (PMID:32179078)
• Methylomic analysis identifies C11orf87 as a novel epigenetic biomarker for GI cancers. (PMID:33886682)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	si:dkey-35i13.1	ENSDARG00000097648
mus_musculus	AI593442	ENSMUSG00000078307
rattus_norvegicus	C8h11orf87	ENSRNOG00000025463

Protein

Protein identifiers

Uncharacterized protein C11orf87 — Q6NUJ2 (reviewed: Q6NUJ2)

All UniProt accessions (2): A0A158RFU1, Q6NUJ2

UniProt curated annotations — full annotation on UniProt →

Subcellular location. Membrane.

RefSeq proteins (1): NP_997528* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR037670	C11orf87	Family

UniProt features (12 total): compositionally biased region 4, topological domain 2, signal peptide 1, chain 1, glycosylation site 1, sequence conflict 1, transmembrane region 1, region of interest 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q6NUJ2-F1	58.55	0.08

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Glycosylation sites (1): 26

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 141 (showing top): ATF_B, GCACCTT_MIR18A_MIR18B, TGGTGCT_MIR29A_MIR29B_MIR29C, RRAGTTGT_UNKNOWN, MYOGENIN_Q6, LFA1_Q6, GCANCTGNY_MYOD_Q6, chr11q22, TATTATA_MIR374, CREBP1_Q2, GGGTGGRR_PAX4_03, CAGCTG_AP4_Q5, AGGCACT_MIR5153P, CREB_Q4, ATF1_Q6

GO Biological Process (0):

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (1): membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
binding	1
cellular anatomical structure	1

Protein interactions and networks

STRING

228 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
C11orf87	OR5W2	Q8NH69	507
C11orf87	POU2AF2	Q8IXP5	479
C11orf87	CCT8L2	Q96SF2	479
C11orf87	POU2AF3	A8K830	468
C11orf87	TMEM17	Q86X19	461
C11orf87	TMEM87A	Q8NBN3	448
C11orf87	HOATZ	Q6PI97	430
C11orf87	ARHGAP20	Q9P2F6	400
C11orf87	PLEKHH2	Q8IVE3	395
C11orf87	BTG4	Q9NY30	376
C11orf87	ZC3H12C	Q9C0D7	371
C11orf87	COXFA4L3	Q9C002	362
C11orf87	OLFML2A	Q68BL7	328
C11orf87	LAYN	Q6UX15	326
C11orf87	TMEM115	Q12893	325

IntAct

69 interactions, top by confidence:

A	B	Type	Score
C11orf87	KRTAP10-8	psi-mi:“MI:0915”(physical association)	0.720
KRTAP10-8	C11orf87	psi-mi:“MI:0915”(physical association)	0.720
C11orf87	KRTAP5-9	psi-mi:“MI:0915”(physical association)	0.560
KRTAP10-5	C11orf87	psi-mi:“MI:0915”(physical association)	0.560
KRTAP10-9	C11orf87	psi-mi:“MI:0915”(physical association)	0.560
C11orf87	TNS2	psi-mi:“MI:0915”(physical association)	0.560
KRT40	C11orf87	psi-mi:“MI:0915”(physical association)	0.560
NOTCH2NLA	C11orf87	psi-mi:“MI:0915”(physical association)	0.560
C11orf87	RBPMS	psi-mi:“MI:0915”(physical association)	0.560
KRTAP5-9	C11orf87	psi-mi:“MI:0915”(physical association)	0.560
C11orf87	KRTAP10-9	psi-mi:“MI:0915”(physical association)	0.560
C11orf87	KRT40	psi-mi:“MI:0915”(physical association)	0.560
RBPMS	C11orf87	psi-mi:“MI:0915”(physical association)	0.560
C11orf87	KRTAP10-5	psi-mi:“MI:0915”(physical association)	0.560
C11orf87	KRTAP19-1	psi-mi:“MI:0915”(physical association)	0.560
KRTAP12-3	C11orf87	psi-mi:“MI:0915”(physical association)	0.560
C11orf87	KRTAP2-4	psi-mi:“MI:0915”(physical association)	0.560
KRTAP6-3	C11orf87	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (59): C11orf87 (Two-hybrid), C11orf87 (Two-hybrid), C11orf87 (Two-hybrid), C11orf87 (Two-hybrid), C11orf87 (Two-hybrid), C11orf87 (Two-hybrid), C11orf87 (Two-hybrid), C11orf87 (Two-hybrid), C11orf87 (Two-hybrid), C11orf87 (Two-hybrid), C11orf87 (Two-hybrid), C11orf87 (Two-hybrid), C11orf87 (Two-hybrid), C11orf87 (Two-hybrid), C11orf87 (Two-hybrid)

ESM2 similar proteins: A0A1B0GU29, A6NLX4, A6QNY1, A9CBA0, B7ZWI3, O14669, O88472, P14784, P16297, P25918, P26896, Q0VFL4, Q13651, Q32M26, Q38J84, Q38J85, Q3SYS8, Q58CT8, Q5BK39, Q5EAA5, Q5HZE8, Q5NCP0, Q5RCL0, Q64322, Q68DV7, Q6AXS2, Q6AXU5, Q6NUJ2, Q6UWV7, Q86UW2, Q8BHB3, Q8BLR5, Q8BSU2, Q8C353, Q8C708, Q8K1T1, Q8MII8, Q8N6P7, Q8NET5, Q8R182

Diamond homologs: Q0VFL4, Q32M26, Q569A3, Q5RCL0, Q6NUJ2, Q9BGX9

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 22 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Keratinization	12	44.6×	6e-18

Disease & clinical

Clinical variants and AI predictions

ClinVar

3 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	2
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

464 predictions. Top by Δscore:

Variant	Effect	Δscore
11:109422263:GGT:G	donor_loss	1.0000
11:109422264:G:T	donor_loss	1.0000
11:109422265:T:A	donor_loss	1.0000
11:109422264:G:GG	donor_gain	0.9900
11:109423373:AGCCT:A	acceptor_gain	0.9900
11:109423374:GCCTG:G	acceptor_gain	0.9900
11:109422839:G:T	donor_gain	0.9700
11:109423373:A:AG	acceptor_gain	0.9700
11:109423374:G:GG	acceptor_gain	0.9700
11:109423374:GCCT:G	acceptor_gain	0.9700
11:109423423:G:GA	donor_gain	0.9700
11:109422831:C:T	donor_gain	0.9600
11:109422839:G:GT	donor_gain	0.9600
11:109423422:T:TA	donor_gain	0.9600
11:109423928:G:GT	donor_gain	0.9600
11:109425542:G:GT	donor_gain	0.9600
11:109422830:G:GT	donor_gain	0.9400
11:109422898:G:GT	donor_gain	0.9400
11:109423374:GC:G	acceptor_gain	0.9400
11:109422259:TCC:T	donor_gain	0.9300
11:109422832:AG:A	donor_gain	0.9300
11:109422835:G:GG	donor_gain	0.9300
11:109422844:G:GA	donor_gain	0.9300
11:109422899:G:T	donor_gain	0.9300
11:109424215:G:GA	donor_gain	0.9300
11:109427889:A:G	acceptor_gain	0.9300
11:109422263:GGTA:G	donor_gain	0.9200
11:109422264:GT:G	donor_gain	0.9200
11:109425176:A:T	donor_gain	0.9200
11:109422259:TCCAG:T	donor_gain	0.9100

AlphaMissense

1254 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
11:109423850:T:C	C73R	0.999
11:109423877:T:C	F82L	0.998
11:109423879:C:A	F82L	0.998
11:109423879:C:G	F82L	0.998
11:109423891:G:C	K86N	0.998
11:109423891:G:T	K86N	0.998
11:109423935:A:G	Y101C	0.997
11:109423912:G:C	K93N	0.996
11:109423912:G:T	K93N	0.996
11:109423830:T:A	V66D	0.995
11:109423833:T:A	L67Q	0.995
11:109423833:T:G	L67R	0.995
11:109423908:G:C	R92P	0.995
11:109423914:T:C	M94T	0.995
11:109423934:T:C	Y101H	0.995
11:109423824:T:A	L64Q	0.994
11:109423824:T:C	L64P	0.994
11:109423889:A:G	K86E	0.994
11:109423890:A:T	K86M	0.994
11:109423903:G:C	K90N	0.994
11:109423903:G:T	K90N	0.994
11:109423935:A:C	Y101S	0.994
11:109423842:T:A	L70H	0.993
11:109423824:T:G	L64R	0.992
11:109423842:T:C	L70P	0.992
11:109423842:T:G	L70R	0.992
11:109423854:T:C	L74P	0.992
11:109423899:T:C	M89T	0.992
11:109423941:G:C	R103P	0.992
11:109423869:T:C	L79P	0.991

dbSNP variants (sampled 300 via entrez): RS1000180961 (11:109426363 A>G), RS1000443924 (11:109422170 G>A,C), RS1000587406 (11:109428517 A>T), RS1000636210 (11:109426699 A>C), RS1000641558 (11:109422150 G>A), RS1000770630 (11:109423424 G>A,C), RS1001025948 (11:109421745 G>A), RS1001504682 (11:109421505 G>C), RS1001744806 (11:109427836 C>G,T), RS1001774517 (11:109428035 T>C), RS1001954831 (11:109423187 A>G), RS1002075515 (11:109429554 T>A), RS1002238651 (11:109422922 G>A), RS1002617175 (11:109420367 C>A), RS1002739539 (11:109426228 G>T)

Disease associations

OMIM: gene `` | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

10 associations (top):

Study	Trait	p-value
GCST002539_7	Schizophrenia	4.000000e-08
GCST004881_6	Knee osteoarthritis	7.000000e-07
GCST004946_119	Schizophrenia	2.000000e-08
GCST006803_49	Schizophrenia	7.000000e-06
GCST007095_22	Systolic blood pressure	9.000000e-06
GCST007095_23	Systolic blood pressure	9.000000e-06
GCST007099_25	Systolic blood pressure	4.000000e-08
GCST007201_122	Schizophrenia	2.000000e-08
GCST007201_321	Schizophrenia	2.000000e-08
GCST012306_10	Bipolar disorder	7.000000e-06

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0006335	systolic blood pressure

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

19 total (human), top 19 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases expression, affects cotreatment, increases expression	5
entinostat	affects cotreatment, increases expression	2
propionaldehyde	decreases expression	1
trichostatin A	increases expression	1
zinc chromate	decreases expression, increases abundance	1
chromium hexavalent ion	decreases expression, increases abundance	1
pentabromodiphenyl ether	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
nutlin 3	affects cotreatment, increases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	decreases expression	1
dorsomorphin	affects cotreatment, increases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Arsenic Trioxide	decreases expression	1
Benzo(a)pyrene	affects methylation, increases methylation	1
Cisplatin	increases expression	1
Dactinomycin	affects cotreatment, increases expression	1
Endosulfan	decreases expression	1
Lead	affects expression	1
Plant Extracts	affects cotreatment, decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.